Akili sees FY23 total operating expenses $55M-$60M

Sees FY24 total operating expenses $42M-$27M. Cash, cash equivalents, and short-term investments are expected to be sufficient to fund current and planned operations into the second half of 2025. By late 2025, non-prescription business model expected to operate at 60-70% gross margins.